Advertisement
Australia markets close in 23 minutes

  • ALL ORDS

    8,078.60
    -39.70 (-0.49%)
     

  • ASX 200

    7,807.30
    -40.80 (-0.52%)
     

  • AUD/USD

    0.6625
    +0.0004 (+0.06%)
     

  • OIL

    76.93
    -0.64 (-0.83%)
     

  • GOLD

    2,368.40
    -24.50 (-1.02%)
     

  • Bitcoin AUD

    104,744.74
    -694.55 (-0.66%)
     

  • CMC Crypto 200

    1,511.13
    -15.28 (-1.00%)
     

  • AUD/EUR

    0.6118
    +0.0008 (+0.12%)
     

  • AUD/NZD

    1.0830
    -0.0028 (-0.26%)
     

  • NZX 50

    11,809.48
    +77.20 (+0.66%)
     

  • NASDAQ

    18,705.20
    -8.59 (-0.05%)
     

  • FTSE

    8,370.33
    -46.12 (-0.55%)
     

  • Dow Jones

    39,671.04
    -201.95 (-0.51%)
     

  • DAX

    18,680.20
    -46.56 (-0.25%)
     

  • Hang Seng

    18,872.59
    -323.01 (-1.68%)
     

  • NIKKEI 225

    39,073.84
    +456.74 (+1.18%)
     

Here's What Key Metrics Tell Us About Insulet (PODD) Q1 Earnings

Zacks Equity Research
·2-min read

Insulet (PODD) reported $441.7 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 23.4%. EPS of $0.73 for the same period compares to $0.23 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $423.52 million, representing a surprise of +4.29%. The company delivered an EPS surprise of +87.18%, with the consensus EPS estimate being $0.39.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

ADVERTISEMENT

Here is how Insulet performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Revenue- International Omnipod: $115.30 million compared to the $106.32 million average estimate based on six analysts. The reported number represents a change of +16.9% year over year.

  • Revenue- U.S. Omnipod: $317.70 million versus $311.93 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +22.7% change.

  • Revenue- Total Omnipod: $433 million compared to the $418.25 million average estimate based on six analysts. The reported number represents a change of +21.1% year over year.

  • Revenue- Drug Delivery: $8.70 million versus $5.56 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +1640% change.

View all Key Company Metrics for Insulet here>>>

Shares of Insulet have returned -1% over the past month versus the Zacks S&P 500 composite's -0.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Insulet Corporation (PODD) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research